Back

Clinical reality and challenges with familial hypercholesterolemia patients management. 2024 results from the Regional Center for Rare Diseases (RCRD) Registry in Poland

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Familial hypercholesterolaemia and cardiovascular risk Lipids ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Maciej Banach

Medical University of Lodz, Lodz (Poland)

7 More presentations in this session

Presentation thumbnail
Impact of addressing modifiable risk factors on the 10-year risk of cardiovascular disease in individuals with familial hypercholesterolemia: a causal analysis utilising UK biobank
Mr C. Stevens (London, GB)
Abstract Slides Video
Presentation thumbnail
Impact of the severe familial hypercholesterolemia status on atherosclerotic risks
Doctor H. Tada (Kanazawa, JP)
Abstract Slides Video
Presentation thumbnail
The effectiveness and barrier of reverse cascade screening for paediatric familial hypercholesterolaemia
Doctor R. Tani (Kagawa, JP)
Abstract Slides Video
Presentation thumbnail
Lipoprotein(a) levels and cholesterol efflux capacity: inverse association and impact on atherosclerosis in familial hypercholesterolemia patients on lipid-lowering therapy
Doctor M. Ogura (Urayasu, JP)
Abstract Slides Video
Presentation thumbnail
Screening for subclinical atherosclerosis in patients clinically diagnosed with familial hypercholesterolemia and determination of imaging-guided patient management strategy
Doctor M. Deniz (Istanbul, TR)
Abstract Slides Video

Access the full session

Session thumbnail
Familial hypercholesterolaemia and cardiovascular risk

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Long-term survival of heFH or ACS patients on PCSK9 targeted therapy based on the real-life data from poland
thumbnail
Congress Presentation
The PCSK9 targeted therapy - the best strategy to prevent cardiovascular complications in very high-risk patients in poland. Real-life data from the national health found B101 reimbursement program
thumbnail
Congress Presentation
The prevalence, patients characteristics and risk factors of hyper-Lp(a)-emia in the Polish population. The first results from the PMMHRI-Lp(a) Registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources